Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development

Journal of Clinical Investigation

Volumn 98, Issue 10, 1996, Pages 2201-2208

  Shen, Jianhe ^a   Herderick, Ed ^b   Cornhill, J Fredrick ^c   Zsigmond, Eva ^a   Kim, Han Seob ^a   Kühn, Hartmut ^d   Guevara, Natalia V ^a   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

oxidized lipoproteins; quantitative morphometry; transgenic rabbits; Watanabe heritable hyperlipidemic rabbits

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; HIGH DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRANSGENIC ANIMAL;

EID: 0029829533     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119029     Document Type: Article

References (36)

1. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
2. Parthasarathy, S., and N. Santanam. 1994. Mechanisms of oxidation, antioxidants, and atherosclerosis. Curr. Opin. Lipidol. 5:371-375.
3. Yla-Herttuala, S., W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 8:1086-1095.
4. Haberland, M.E., D. Fong, and L. Cheng. 1988. Malondialdehyde-altered LDL occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science (Wash. DC). 241:215-218.
5. Palinski, W., M.E. Rosenfeld, S. Yla-Herttuala, G.C. Gurtner, S.S. Socher, S.W. Butler, S. Parthasarathy, T.E. Carew, D. Steinberg, and J.L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1372-1376.
6. Kita, T., Y. Nagano, M. Yokode, K. Ishii, N. Kume, A. Ooshima, H. Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:5928-5931.
7. Carew, T.E., D.C. Schwerke, and D. Steinberg. 1987. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:7725-7729.
8. Bjorkhem, I., A. Henriksson-Freyschuss, O. Breyer, U. Diczfalasy, L. Berglund, and P. Henriksson. 1991. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11:15-22.
9. Sparrow, C.P., T.W. Doebber, J. Olszewski, M.S. Wu, J. Ventre, K.A. Stevens, and Y. Chao. 1992. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J. Clin. Invest. 89:1885-1891.
10. Salonen, J.T., S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski, and J.L. Witztum. 1992. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet (N. Am. Ed.) 339:883-887.
11. Shen, J., H. Kühn, A. Petho-Schramm, and L. Chan. 1995. Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specifc expression and variable positional specificity of the transgenic enzyme. FASEB J. 9:1623-1631.
12. Sigal, E., D. Grumberger, J.R. Cashman, C. Craik, G.H. Caughey, and J.A. Nadel. 1988. Molecular cloning and primary structure of human 15-lipoxygenase. Biochem. Biophys. Res. Comm. 157:457-464.
13. Bonifer, C., M. Vidal, F. Grosveld, and A.E. Sippel. 1990. Tissue specific and position independent expression of the complete gene domain for chicken lysozyme in transgenic mice. EMBO (Eur. Mol. Biol. Organ.) J. 9:2843-2848.
14. Li, J., B. Fang, R.C. Eisensmith, X.H.C. Li, I. Nasonkin, Y. Lin-Lee, M.-P. Mims, A. Hughes, C.D. Montgomery, J.D. Robert et al. 1995. In vivo gene therapy for hyperlipidemia: phenotypic correction in watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J. Clin. Invest. 95:768-773.
15. Lindgren, F.T., L.C. Jensen, and F.T. Hatch. 1972. The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins. G.J. Nelson, editor. John Wiley and Sons, Inc. Interscience Division, New York, 181-274.
16. Rossman, M.D., P. Dhien, A. Cassizzi-Cprek, J.A. Elias, A. Holian, and A.D. Schreiber. 1986. The binding of monomeric IgG to human blood monocytes and alveolar macrophages. Am. Rev. Resp. Dis. 133:292-297.
17. Guzman, M.A., C.A. McMahan, H.C. Mcgill, J.P. Strong, C. Tejada, C. Restrepo, D.A. Eggen, W.B. Robertson, and L.A. Solberg. 1968. Selected methodolgic aspects of the international atherosclerosis project. Lab. Invest. 18: 479-497.
18. Cornhill, J.F., W.A. Barrett, E.E. Herderick, R.W. Mahley, and D.L. Fry. 1985. Topographic study of sudanophillic lesions in cholesterol-fed minipigs by image analysis. Artherosclerosis. 5:415-426.
19. Conrad, D.J., H. Kühn, M. Mulkins, E. Highland, and E. Sigal. 1991. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl. Acad. Sci. USA. 89:217-221.
20. Yla-Herttuala, S., M.E. Rosenfeld, C.K. Glass, E. Sigal, J.L. Witztum, and D. Steinberg. 1990. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesion. Proc. Natl. Acad. Sci. USA. 87:6959-6963.
21. Yla-Herttuala, S., J. Luoma, H. Viita, T. Hiltunen, T. Sisto, and T. Nikkari. 1995. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein addusts characteristic of oxidized low density lipoprotein. J. Clin. Invest. 95:2692-2698.
22. Elinder, L.S., and G. Walldius. 1994. Antioxidants and atherosclerosis progression: unsolved questions. Curr. Opin. Lipidol. 5:265-268.
23. Chait, A., and J.W. Heinecke. 1994. Lipoprotein modification: cellular mechanisms. Curr. Opin. Lipidol. 5:365-370.
24. Sparrow, C.P., S. Parthasarathy, and D. Steinberg. 1988. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimic cell-mediated oxidative modification. J. Lipid Res. 29:745-753.
25. Kühn, H., J. Belkner, H. Suzuki, and S. Yamamoto. 1994. Oxidative modification of human lipoproteins by lipoxygenesis of different positional specificaties. J. Lipid Res. 35:1749-1759.
26. Benz, D.J., M. Mol, M. Ezaki, M. Mori-Ito, I. Zelan, A. Miyanohara, T. Friedmann, S. Parthasarathy, D. Steinberg, and J.L. Witztum. 1995. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270: 5191-5197.
27. Rankin, S.M., S. Parthasarathy, and D. Steinberg. 1991. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 32:449-456.
28. Yla-Herttuala, S., M.E. Rosenfeld, S. Parthasarathy, E. Sigal, T. Sarkioja, J.L. Witztum, and D. Steinberg. 1991. Gene expression in macrophage-rich human atherosclerotic lesions. J. Clin. Invest. 87:1146-1152.
29. Kühn, H., J. Belkner, S. Zaiss, T. Fahrenklemper, and S. Wohlfeil. 1994. Involvement of 15-lipoxygenase in early stages of atherogenesis. J. Exp. Med. 179:1903-1911.
30. Simon, T.C., A.N. Makheja, and J.M. Bailey. 1989. The induced lipoxygenase in atherosclerotic aorta converts linoleic acid to the platelet chemorepellant factor 13-HODE. Throm. Res. 55:171-178.
31. Buchanan, M.R., R.W. Butt, Z. Magas, J.V. Ryn, J. Hirsh, and D.J. Nazir. 1985. Endothelial cells produce a lipoxygenase derived chemo-repellent which influences platelet/endothelial cell interactions - effect of aspirin and salicylate. Thromb. Haemostasis. 53:306-311.
32. Buchanan, M.R., T.A. Haas, M. Lagarde, and M. Guichardant. 1985. 13-Hydroxyoctadeca-dienoic acid is the vessel wall chemorepellent factor, Lox. J. Biol. Chem. 260:16056-16059.
33. Haas, T.A., E. Bastida, K. Nakamura, F. Hullin, L. Admirall, and M.R. Buchanan. 1988. Binding of 13-HODE and 5-, 12- and 15-HETE to endothelial cells and subsequent platelet, neutrophil and tumor cell adhesion. Biochim. Biophys. Acta. 961:153-159.
34. Setty, B.N.Y., M. Berger, and M.J. Stuart. 1987. 13-Hydroxyoctadecadienoic acid (13-HODE) stimulates prostacyclin production by endothelial cells. Biochem. Biophys. Res. Commun. 146:502-509.
35. Setty, B.N.Y., M. Berger, and M.J. Stuart. 1987. 13-Hydroxyoctadeca-9, 11-dienoic acid (13-HODE) inhibits thromborane A2 synthesis, and stimulates 12-HETE production in human platelets. Biochem. Biophys. Res. Commun. 148:528-533.
36. Simon, T.C., A.N. Makheja, and J.M. Bailey. 1990. Relationship of vascular 15-lipoxygenase induction to atherosclerotic plaque formation in rabbits. Prostaglandins, Leukot. Essent. Fatty Acids. 41:273-278.